Oaktree Acquisition Corp. III Life Sciences (OACC) Financial Statements
Industry: Blank Checks
In fiscal 2025, Oaktree Acquisition Corp. III Life Sciences reported revenue of $0. Net income was $7.3M, or $0.30 per diluted share. Operating activities generated -$422,079 of cash. At fiscal year end, Oaktree Acquisition Corp. III Life Sciences held $203.1M in total assets against $8.3M in total liabilities, including $1.4M of cash and equivalents.
Open the full interactive Oaktree Acquisition Corp. III Life Sciences financials → Quarterly statements, key ratios, valuation history and price charts.
Oaktree Acquisition Corp. III Life Sciences Key Stats
| Share Price | $10.75 |
|---|---|
| Market Cap | $206.4M |
| P/E Ratio | 35.8 |
| 52-Week Range | $10.50 – $10.80 |
| Shares Outstanding | 19.2 million (basic, 2026 Q2) |
Oaktree Acquisition Corp. III Life Sciences Income Statement
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Cost of Goods Sold | $0 |
| Gross Profit | $0 |
| Operating Income | -$1.2M |
| Pre-Tax Income | $7.3M |
| Net Income | $7.3M |
| Diluted EPS | $0.30 |
Oaktree Acquisition Corp. III Life Sciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | $2.0M | $1.8M | $1.4M | $1.6M |
| Diluted EPS | $0.08 | — | $0.06 | $0.07 |
Oaktree Acquisition Corp. III Life Sciences Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $1.4M |
| Current Assets | $1.5M |
| Total Assets | $203.1M |
| Current Liabilities | $1.3M |
| Total Liabilities | $8.3M |
| Shareholders' Equity | -$6.8M |
Oaktree Acquisition Corp. III Life Sciences Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$422,079 |
| Cash From Investing | $500,000 |
| Cash From Financing | $0 |
Figures from Oaktree Acquisition Corp. III Life Sciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Oaktree Acquisition Corp. III Life Sciences financials page for every line item.
Oaktree Acquisition Corp. III Life Sciences Company Profile
| Ticker | OACC |
|---|---|
| Exchange | Nasdaq |
| Industry | Blank Checks |
| Headquarters | Los Angeles, California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0002029769 |
Frequently Asked Questions
What was Oaktree Acquisition Corp. III Life Sciences' revenue in fiscal 2025?
Oaktree Acquisition Corp. III Life Sciences (OACC) reported revenue of $0 for fiscal 2025.
What was Oaktree Acquisition Corp. III Life Sciences' net income in fiscal 2025?
Oaktree Acquisition Corp. III Life Sciences reported net income of $7.3M for fiscal 2025.
What was Oaktree Acquisition Corp. III Life Sciences' earnings per share (EPS) in fiscal 2025?
Oaktree Acquisition Corp. III Life Sciences' diluted EPS was $0.30 for fiscal 2025 (adjusted for any later stock splits).
What was Oaktree Acquisition Corp. III Life Sciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Oaktree Acquisition Corp. III Life Sciences reported revenue of $0.
How many shares of Oaktree Acquisition Corp. III Life Sciences are outstanding?
Oaktree Acquisition Corp. III Life Sciences reported a weighted average of 19.2 million basic shares outstanding in 2026 Q2.
What is Oaktree Acquisition Corp. III Life Sciences' market cap?
Based on its latest closing price, Oaktree Acquisition Corp. III Life Sciences (OACC) has a market capitalization of about $206.4M.
When does Oaktree Acquisition Corp. III Life Sciences' fiscal year end?
Oaktree Acquisition Corp. III Life Sciences' fiscal year end, as registered with the SEC, is December 31.
Where is Oaktree Acquisition Corp. III Life Sciences headquartered?
Oaktree Acquisition Corp. III Life Sciences lists its business address in Los Angeles, California in its SEC filings.